Raymond Comenzo, MD
Hematology & Oncology · Boston, MANPI 1750352787
Payments from drug & device makers
Across 385 payments — averaging $3675.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$749K
- AstraZeneca$407K
- Takeda Pharmaceuticals U.S.A., Inc.$72K
- Amgen$65K
- Eli Lilly$30K
- Pfizer$29K
- plus $63K from 8 others
Across 1 payment — averaging $144.38 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$144
What the payments were for
- Consulting fees$68,620100%
- Travel & lodging$880%
- Food & beverage$2200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 323 | $748,604 |
| AstraZeneca | 10 | $407,022 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $72,163 |
| Amgen | 1 | $64,999 |
| Eli Lilly | 2 | $30,070 |
| Pfizer | 5 | $28,735 |
| Sanofi-aventis U.S. LLC | 9 | $23,246 |
| Genentech, Inc. | 5 | $14,852 |
| Alnylam Pharmaceuticals Inc. | 8 | $11,128 |
| Janssen Global Services, LLC | 3 | $8,740 |
| Sanofi US Services Inc. | 2 | $5,214 |
| Seagen Inc. | 1 | $134 |
| Karyopharm Therapeutics Inc. | 1 | $82 |
| E.r. Squibb & Sons, L.L.C. | 1 | $63 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DARZALEX$33,680
- SARCLISA$19,770
- ISATUXIMAB$8,690
- NINLARO$2,640
- Venclexta$1,980
How this compares
$1,415,051 in reported general payments places this provider in the 80th percentile of 374 hematology & oncology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Boston
- Matthew DavidsBoston$58.6M
- Nadine TungBoston$32.4M
- Jorge CastilloBoston$31.2M
- Daniel DeangeloBoston$28.5M
- Sara TolaneyBoston$20.3M
- Paul RichardsonBoston$17.2M
- Amir FathiBoston$14.8M
- Jacqueline GarciaBoston$13.6M
- John KorethBoston$12.8M
- David ReardonBoston$12M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.